VIVS חוב לטווח קצר להון Organovo Holdings Inc.

VivoSim Labs Inc (VIVS) maintains its primary capacities in US bioprinting centers, where process reliability is ensured through the redundancy of high-precision systems. The workforce integrates bio-ink experts and printing engineers, while the company actively recruits clinical validation specialists. The stock price action with the 0.00 indicator reflects the market trend. The business relies on the innovative production of tissues for pharmaceutical companies, minimizing their costs during drug development.

This indicator assesses the level of short-term debt relative to equity, whereby the ratio of the firm's short-term debt to equity determines the company's dependence on obligations with maturities of up to one year, which is critical for maintaining the operational stability of medical supply chains and the seamless logistics of precision diagnostic equipment for VivoSim Labs Inc (VIVS).